Corporate Counsel
  • Home
  • News
  • Surveys
  • Resources
  • Lawjobs
  • Advertise
  • Subscribe
  • Bookstore
  • Contact

Topics » IP Insider | Labor & Employment | From the Experts | On the Job | Moves | DC Watch | International

Home > Rumbles From Afar

Font Size: increase font decrease font

Previous

  • 1
  • 2

Rumbles From Afar

December 1, 2012

  •    
  •    
  •    
  •      
 

Novartis insists that Glivec meets the criteria for patentability. Like the other drug companies, it argues that allowing generic drug makers to sell copies of its patented drugs will discourage innovation. "We strongly believe safeguarding incentives for innovation through the granting of patents leads to better medicines for patients without options," says Novartis spokeswoman Julie Masow.

Novartis appealed the patent office's decision, and the case has wended its way through the courts. India's Supreme Court heard the case in September, and it could issue a ruling before the end of the year.

International aid organizations fear that a ruling for the drug company would represent a big setback for the public. Says Rehman: "At the end of the day, it's the patients who suffer."

Since the Novartis fight began six years ago, other drug companies have lost big battles in India over top-selling and life-saving drugs. In 2009 India's patent authority rejected applications filed by Gilead Sciences for Viread, a widely prescribed drug used to treat HIV. In 2010 it revoked the local patent held by Roche on its antiviral drug Valcyte, which is used to treat HIV-AIDS patients and to prevent infection in patients who have received an organ transplant.

In response to the chorus of complaints, international aid groups say that the drugmakers are blowing the issue out of proportion by focusing on these losses. They point out that the majority of patent applications in India are not rejected, and the companies are profiting from their patents.

But Big Pharma has another concern. The recent compulsory licensing order in India sparked fears that other nations would follow its lead. Multilateral agreements have given poorer countries the right to order compulsory licenses when public health is at stake. And countries like Malaysia have made use of them in the past.

Subsequent developments suggest that these fears were not unfounded. In June, China overhauled its IP laws. The changes allow the Chinese government to issue compulsory licenses to local companies to produce generic versions of patented drugs during states of emergency or unusual circumstances, or when the public interest is at stake.

Three months later, the companies' worst fears were realized. The government of Indonesia overrode the patents on seven hepatitis and HIV drugs. The companies affected were Merck & Co., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Abbott Laboratories, and Gilead. An estimated 310,000 people are living with HIV in Indonesia. The country justified its actions by citing the need to improve patient access. Now Big Pharma and international aid organizations are watching and waiting to see who fires next in this escalating intellectual property war.

Previous

  • 1
  • 2


Subscribe to Corporate Counsel

You must be signed in to comment on an article

Find similar content

Companies, agencies mentioned

    
  • Gilead Sciences for Viread
  • Intellectual Property Appellate Board
  • Cipla Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Doctors Without Borders
  • Supreme Court
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • World Trade Organization
  • Pfizer Inc.
  • Bayer AG
  • Roche Holding AG

Key categories

    
  • Corporate & Business Law

Most viewed stories

    
  1. Best Legal Departments 2013
    •      
  2. 6 Things In-House Counsel Must Know About E-Discovery
    •      
  3. 3-D Printing: The Next Big Thing in IP Law?
    •      
  4. Bristol-Myers Squibb: The Caped Crusaders
    •      
  5. U.S. Legal System Ranked as Most Costly
    •      
lawjobs.com

TOP JOBS

MORE JOBS

POST A JOB

From the Law.com Network

Taking the Reins of Legal Department Operations

In-House Law: Now in 3-D!

Simpson Helps Yahoo, Tumblr Connect for $1 Billion Deal

Kasowitz Benson Launches in Los Angeles

Contrite Companies Can Win Forgiveness in Bribery Cases
  •      
    • Subscription Required

Plaintiffs Want to See Toyota's 'Crown Jewels'
  •      
    • Subscription Required

Collaboration Is Key to Defending Cyberattacks

Stanford Law Builds on Role as Legal Tech Incubator

Prolific ADA Plaintiff Faces Nemesis in Harassment Suit

Ullyot Exit Closes Chapter for Facebook

Rothstein Bankruptcy Trustee Files New Reorganization Plan
  •      
    • Subscription Required

Fla. Bar Wants Disbarment for Former Judge
  •      
    • Subscription Required

Appellate Division To Roll Out Electronic Case Filing System

Court Limits Liability for Injury Or Death of One Invited To Help
  •      
    • Subscription Required

The Affordable State-Specific Practice Solution
Available in NY, NJ, PA and CT editions - research, draft and prepare even the most complex cases with ease.

Court Officials Seek to Reform Process of Naming Acting Justices

NYC Defends Police Department's Use of Stop-and-Frisk

Lawsuit Testing Federal Porn Regulation Allowed to Survive

Ex-College QB Can Press Claim Over EA's Video Game
  •      
    • Subscription Required

Law Schools Are Looking Beyond LSATs, Says Mich. Dean

Is Freezing Your Eggs the Solution?

Water Warriors: Local Governments Bring Pollution Suits
  •      
    • Subscription Required

Sanction Reversed; Filing of Sexually Explicit Chat OKd
  •      
    • Subscription Required

Brooks Looks To Political Ally For Criminal Defense

Attorney Fee Hearing in Waffle House Sex Case Heats Up
  •      
    • Subscription Required

Corporate Bribery Case Part Of National Trend
  •      
    • Subscription Required

Court Continues To Grant Lawyers Fraud Immunity
  •      
    • Subscription Required

  • About |
  • ALM Properties |
  • ALM Reprints |
  • Customer Support |
  • Privacy Policy |
  • Terms & Conditions |
  • ALM User License Agreement
ALM Media